



Syndax to Present at 2015 BIO CEO & Investor Conference

WALTHAM, Mass., Feb. 5, 2015 -- Syndax Pharmaceuticals, Inc., today announced that chief executive officer, Arlene Morris, will be presenting a corporate overview at the 17th Annual BIO CEO and Investor Conference at 10:00 a.m. EST on Monday, February 9, 2015, in the Park South room at the Waldorf Astoria Hotel in New York City.

About Syndax

Syndax is developing Entinostat, an oral, highly selective HDAC inhibitor with epigenetic and immunomodulatory activity that is being evaluated in multiple combination approaches for the treatment of patients with therapy-resistant cancers. Entinostat has been designated a Breakthrough Therapy by the FDA when used in combination with exemestane in HR+ advanced (locally advanced or metastatic) breast cancer. A pivotal Phase 3 clinical study combining entinostat with exemestane for the treatment of hormone receptor-positive metastatic breast cancer is currently enrolling. Syndax is also developing an immuno-oncology platform to improve responsiveness to checkpoint inhibitors based on entinostat's ability to down-regulate immune suppressor cells. Syndax holds rights to entinostat in most major markets.